Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.90 |
| ▸ | TP53 | P04637 | 2/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | STAT1 | P42224 | 1/20 | 0.77 |
| ▸ | GFER | P55789 | 1/20 | 0.71 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28240671 | 0.88 | RAB9A (0.85) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL28906662 | 0.88 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL1143708 | 0.87 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL8297120 | 0.86 | SMN1; SMN2 (0.75) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL14132986 | 0.83 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL6581818 | 0.83 | NPY5R (1.00) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL6582516 | 0.82 | NPY5R (0.76) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL8303452 | 0.80 | SMN1; SMN2 (0.66) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL31324278 | 0.78 | SMN1; SMN2 (0.84) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL12615169 | 0.78 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| EP-1257539-B1 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6531478-B2 | For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders | KORDIK CHERYL P (US) | 2003-03-11 | — | — | US | disclosed |
| EP-1257539-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | KORDIK CHERYL P (US) | 2002-05-30 | — | — | US | disclosed |
| WO-2001062737-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | NPY5R, NPY1R, NPY4R | RAB9A 2343/4885SMN1; SMN2 4189/4885NPC1 3099/4885 |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | RAB9A 596/4885SMN1; SMN2 1031/4885NPC1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.